Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Pharmacology - Exam 2 > Parkinson's Disease > Flashcards

Parkinson's Disease Flashcards

1
Q

Which part of the brain is affected by Parkinson’s Diease?

_________

Which neurotransmitters are involved in Parkinson’s Disease?

A

Nigrostriatal Projection

_______

  1. Dopamine
  2. Acetylcholine
  3. GABA
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is often the earliest sign of Parkinson’s disease?

A

Tremor (Pill Rolling)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What type of Rigidity is expressed in Parkinson’s Disease?

A

Cogwheel type; increased muscle tone

________

Definition:

  • When a limb is bent, it seems to catch at regular points throughout its range of motion, much as a second hand jerks from interval to interval instead of smoothly traversing the face of a clock.
  • muscular rigidity in which passive movement of the limbs (as during a physical examination) elicits ratchet-like start-and stop movements through the range of motion of a joint
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What symptoms make up the clinical syndrome of Parkinson’s disease?

A
  1. Bradykinesia/akinesia
  2. Tremor (“pill rolling”)
  3. Rigidity (“Cogwheel type”)
  4. Impairment of postural balance (shuffling gait; disturbances in gait; falling)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are the autonomic symptoms of Parkinson’s disease?

A
  1. sweating
  2. constipation
  3. hypersalivation
  4. urinary retention
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is the total symptom profile of Parkinson’s Disease?

A

Clinical Syndrome

  1. Bradykinesia/akinesia
  2. Tremor (“pill rolling”)
  3. Rigidity (“Cogwheel type”)
  4. Impairment of postural balance (shuffling gait;disturbances in gait; falling)

Autonomic symptoms

  1. sweating
  2. constipation
  3. hypersalivation
  4. urinary retention

Other symptoms

  1. mask-like face
  2. weight loss
  3. anorexia
  4. depression
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What does the clinical severity of Parkinson’s Disease correspond to?

A

Loss of dopamine neurons in the substantia nigra pars compacta

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Approximately what level of cell loss of the dopamine neurons in substantia nigra pars compacta results in symptoms?

A

Symptoms appear after >50% cell loss

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Which age group is most common for Parkinson’s Disease?

A

Age 65 and older

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is the basic pathology of Parkinson’s Disease?

A
  • Progressive degeneration of dopamine neurons in substantia nigra pars compacta
  • Disease is progressive, ultimately fatal
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is a significant comorbidity with Parkinson’s Disease?

A

depression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Describe, in detail, the pathophysiology of Parkinson’s Disease in the Nigrostriatal Projection?

A

Nigrostriatal Projection

  • Nigrostriatal Neuron and Cholinergic Interneuron act on striatal GABAergic efferent neuron
  • DA from nigrostriatal neuron is inhibitory; ACh from cholinergic interneuron is excitatory
  • Nigrostriatal neurons die, thus they do not produce DA and Cholinergic interneuron does not die; thus balance is altered toward ACh excitatory
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What are the 6 Pharmacological strategies for treating Parkinson’s Disease?

A
  1. DA replacement (L-DOPA)
  2. Enzyme inhibitors to enhance CNS delivery
  3. MAO-B inhibition to prolong CNS effects
  4. Enhance DA release, block re-uptake
  5. Directly stimulate DA receptors
  6. Anticholinergics (antimuscarinics)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Broadly speaking, what does Pharmacotherapy for Parkinson’s Disease aim to accomplish?

A

Treat the imabalance between striatal cholinergic and dopaminergic activity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

You are seeking to treat Parkinson’s Disease using the pharmacological strategy of DA replacement. What do you use? How does it work?

A

L-DOPA; L-DOPA is a precursor for DA synthesis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is the fate of orally administered L-DOPA?

A

~70% metabolism in GI tract

~27-29% Peripheral Tissues (toxicity)

1-3% Brain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What is L-DOPA utilized instead of DA?

A

L-DOPA is able to traverse the blood/brain barrier; DA is not able to

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

How much of L-DOPA is decarboxylated in the periphery? What side effects does this lead to?

A

~95% of L-DOPA is decarboxylated in the periphery

Peripheral Side Effects

  1. Nausea
  2. Cardiac palpitations and arrythmias
  3. Postural hypotension
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What are the CNS toxicities and side effects of L-DOPA?

A
  1. Psychotic symptoms
  2. Dyskinesias
  3. On-Off Phenomenon
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

The motor CNS toxicities of L-DOPA are due to what? Where?

A

Motor effects due to increased DA in the striatum

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

The psychotic CNS toxicities of L-DOPA are due to what? Where?

A

Psychotic effects due to increased DA in the accumbens

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What causes on-off phenomenon? Describe the “on” phase? Describe the “off” phase? Which enzymes, if inhibited, reduce on-off phenomenon?

A

Cause: Variable CNS metabolism of DA by COMT and MAO-B

______

On-phase: PD symptoms are controlled (but dyskinesias)

_____

Off-phase: PD symptoms are not controlled (may have dystonias/sustained muscle contractions)

______

If COMT and MAO-B are inhibited, on-off phenomenon is reduced

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

3 contraindications of L-DOPA

A
  1. Psychosis (already have too much DA activity)
  2. Melanoma (L-DOPA is precursor for melanin in skin)
  3. Narrow angle glaucoma (due to alpha1 agonist activity at high concentrations of DA which causes an inability of vitreous humor to drain from canal of Schlemm)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Name 3 interactions with other drugs of L-DOPA

A
  1. Nonselective MAO inhibitors (antidepressants)
    • risk of hypertensive crisis (alpha a1 agonism)
    • Exception: Selegeline
  2. Pyridoxine (Vitamin B6)
    • Enhances peripheral metabolism of L-DOPA via L-AAD (more peripheral side effects)
  3. Anti-psychotics
    • Will block effects at DA receptors
25
Q

How long after prescription is L-DOPA most effective for a Parkinson’s Patient? What happens longer term?

A

Most effective first 3-4 years of use. Longer term:

  • Increasing intolerance to side effects (result in need to decrease dose)
  • Decreased effectiveness as more neurons die and thus, less neurons to convert L-DOPA to DA
26
Q

What is L-DOPA’s effectiveness?

A
  • Effective 1/3 pts
  • Somewhat effective 1/3 pts
  • Ineffective 1/3 pts
27
Q

L-DOPA is particularly good at treating which PD symptoms?

A
  • Bradykinesia
  • Akinesia
28
Q

In a younger Parkinson patient, would you recommend L-DOPA as first line therapy?

A

No; most physicians prefer to start young PD patients with something other than L-DOPA

29
Q

If you would like to treat Parkinson’s Disease by employing the strategy of inhibiting the enzyme L-AAD in the periphery to increase delivery of the DA precursor and slow metabolism of CNS DA, what pharmacological agent would you use?

A

Carbidopa

30
Q

What is the mechanism of action of carbidopa?

A
  • Inhibit L-AAD in the periphery
  • BUT; this causes a shunt to an alternate metabolic pathway such that COMT upregulates in the periphery

___________

In order to inhibit COMT use tolcapone or entacapone

31
Q

If you would like to treat Parkinson’s Disease by employing the strategy of inhibiting the enzyme COMT in the periphery to increase delivery of the DA precursor and slow metabolism of CNS DA, what pharmacological agent would you use?

A

Tolcapone or Entacapone

_____

****Tolcapone also inhibits central L-DOPA metabolism by COMT as well

32
Q

What pharmacological agent inhibits BOTH peripheral L-DOPA metabolism AND central L-DOPA metabolism

A

Tolcapone

33
Q

What are the advantages and disadvantages of Enzyme Inhibitors? (Carbidopa, Tolcapone, or Entacapone)

A

Advantages

  1. >75% reduction in the amount of L-DOPA administered
  2. Peripheral side effects are diminished
  3. On-Off phenomenon diminished

Disadvantages

  1. CNS toxicity of L-DOPA (ex. psychosis) can be increased
34
Q

If you would like to treat PD by inhibiting metabolism of MAO-B of CNS dopamine, which pharmacologic agents would you use? What is the mechanism of action?

A

selegeline or rasagiline

_____

Act by inhibiting MAO-B, a precursor to 3,4-dihydroxy Phenylactic acid which is converted by COMT to homovanillic acid, a neurotoxic metabolite

35
Q

How is smoking neuroprotective with regard to Parkinsons?

A
  1. Tobacco smoke inhibits MAO-B
  2. Nicotine is neuroprotective and releases DA
36
Q

What are the advantages and disadvantages of using MAO-B inhibitors for PD? (Selegiline, Rasagiline)

A

Advantages

  1. Allows reduction in L-DOPA use
  2. Reduces “on-off”

Disadvantages

  1. Can worsen L-DOPA CNS side effects
  2. Oral administration causes metabolism to amphetamines
  3. Cannot give in combo with non-selective MAO inhibitors
37
Q

If you wanted to treat Parkinsons Disease by stimulating CNS D2 receptors directly with an agonist, which pharmacological agents would you use?

A
  1. Ropinirole
  2. Pramipexole
38
Q

What are the advantages of D2 agonists (Ropinirole and Pramipexole)?

A
  1. Allows L-DOPA use to be reduced
  2. Alleviates on-off phenomenon
  3. Can be used in patients becoming refractory to L-DOPA
39
Q

Which drugs are sometimes used in younger patients with Parkinson’s Disease prior to L-DOPA?

A
  1. Ropinirole
  2. Pramipexole
40
Q

What are the side effects of CNS D2 receptor agonists?

A

Peripheral

  1. Nausea
  2. Hypotension

CNS

  1. Dyskinesias (lower incidence than L-DOPA)
  2. Psychosis (higher incidence than L-DOPA)
41
Q

Which has a higher incidence of dyskinesias: L-DOPA or Ropinirole/Pramipexole?

A

L-DOPA

42
Q

Which has a higher incidence of psychosis: L-DOPA or Ropinirole/Pramipexole?

A

Ropinirole/Pramipexole

43
Q

What are the contraindications for D2 agonists (Ropinirole/Pramipexole)?

A
  1. Psychosis
  2. Recent MI, peripheral vascular disease (ex. at risk for orthostatic hypotension)
  3. Peptic ulcers (nausea and vomiting will exacerbate these)
44
Q

If you wanted to treat Parkinson’s Diease by enhancing DA release from remaining terminals and inhibit its reuptake, which pharmacological agent would you use?

A

Amatadine

45
Q

What are the therapeutic benefits of enhancing DA release from remaining terminals and inhibiting its reuptake (Amantadine)?

A
  1. Sometimes used as initial therapy
  2. Can reduce bradykinesia, rigidity, and tremor in early stages
  3. Can be used for L-DOPA/Carbidopa fluctuations and dyskinesias
  4. May improve cognition through actions at NMDA receptors

__________

Notes: Benefits may be short-lived

46
Q

What are the side effects of enhancing DA release from remaining terminals and inhibiting its reuptake (Amantadine)?

A
  1. Generally mild
  2. Overdose can produce acute toxic psychosis
47
Q

If you wanted to treat Parkinson’s Disease by creating a rebalance using mascarinic antagonishts, which pharmacological agent would you use?

A

Antimuscarinic (benztropine)

48
Q

Which pharmacological agent can be used in very MILD parkinson’s disaease, especially if TREMOR is the only symptom?

A

antimuscarinic (benztropine)

49
Q

Which pharmacological agent in Parkinson’s Disease works better on tremor and rigidity than on bradykinesia?

A

antimuscarinic (benztropine)

50
Q

True or false: Antimuscarinics like benztropine may be useful in combo with L-DOPA.

A

True

51
Q

What are the side effects of anticholinergics?

A

Peripheral

  1. Dry mouth
  2. Blurred vision
  3. Mydriasis
  4. Urinary retention
  5. Nausea

Central

  1. Drowsiness
  2. Mental slowness, confusion
  3. Inattention
  4. Restlessness
52
Q

OVERALL, for patients with mild symptoms in Parkinson’s Disease, which pharmacological agents would you consider?

A
  1. MAO-B inhibitors (Selegiline/Rasagiline)
  2. amantadine
  3. (in younger patients) anticholinergics
53
Q

OVERALL, in patients with Parkinsons disease, treatment with which parmacological agents will eventually be required?

A

Treatment with a dopaminergic drug, either levodopa or a DA agonist (Ropinirole/Pramipexole)

54
Q

True or false? Treatment of PD should be tailored to the individual patient

A

true

55
Q

True or false? Drug therapy is not obligatory in early PD; many patients can be managed for a time with exercise and lifestyle interventions

A

True

56
Q

Large controlled clinical trials provide convincing evidence for a reduced rate of motor fluctuation in patients in which ___________ are used as initial treatment.

This benefit was, however, accompanied by an increased rate of adverse effects, especially somnolence and hallucinations

A

DA agonists

57
Q

Practitioners prefer _______ as initial therapy in younger patients in order to reduce the occurence of motor complications.

A

DA agoinst

58
Q

Practitioners prefer _________ in older patients or those with substantial comorbidity

A

levodopa/carbidopa

Pharmacology - Exam 2 (14 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions